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A B S T R A C T
Chronic kidney disease (CKD) is accompanied by accumulating levels of uremic solutes in the circulation. Changes in the size and composition of the bile acid pool
have also been observed. We investigated via which mechanisms uremic solutes may interfere with hepatocyte function and thus contribute to altered bile acid
handling. We studied interference on the level of bile acid synthesis by cytochrome P450 7A1 (CYP7A1), explored effects on hepatic bile acid transporters, and
investigated effects on mitochondrial function. In HEK293 cells overexpressing bile salt transporters, we observed that p-cresyl sulfate inhibited Na+-taurocholate
cotransporting polypeptide (NTCP)-mediated uptake of taurocholic acid (TCA), whereas organic anion-transporting polypeptide 1B1 (OATP1B1)-mediated TCA
uptake was increased. Assays in transporter-overexpressing membrane vesicles revealed that kynurenic acid inhibited TCA transport via the bile salt efflux pump
(BSEP), whereas p-cresyl glucuronide and hippuric acid increased TCA efflux via multidrug resistance-associated protein 3 (MRP3). Moreover, indoxyl sulfate
decreased mRNA expression of NTCP, OATP1B3 and CYP7A1 in primary human hepatocytes. Transport studies confirmed a decreased TCA uptake in indoxyl sulfate-
exposed hepatocytes. Decreased hepatocyte viability was found for all seven uremic solutes tested, whereas five out of seven also decreased intracellular ATP levels
and mitochondrial membrane potential. In conclusion, uremic solutes affect hepatic bile acid transport and mitochondrial function. This can contribute to the altered
bile acid homeostasis observed in CKD patients.
1. Introduction
Chronic kidney disease (CKD) is characterized by increasing loss of
kidney-mediated clearance of waste products present in blood and
therefore constitutes a severe burden on patient health. Its prevalence
in developed countries is estimated at 10%, associated with 2% of all
annual health care-related costs (de Zeeuw et al., 2005; Lopez-Novoa
et al., 2010). During CKD, accumulation of uremic solutes is observed in
the circulation. They comprise a group of approximately 100 com-
pounds that are generated as waste products of normal metabolism. For
one class of uremic solutes in particular, removal from blood is not
possible due to a high degree of protein binding, which prevents their
clearance via dialysis treatment (Vanholder et al., 2008).
Besides altered uremic solute levels, bile acid handling is changed
via cross-talk between the kidneys and liver. One study demonstrated
changes in bile acid pool size and composition in CKD patients under-
going dialysis treatment, which returned to normal upon kidney
transplantation (Jimenez et al., 2002). As the effects of uremic solutes
on hepatic drug metabolism and excretion are known to be partly
mediated via hepatic drug transporters (Sun et al., 2004; Tsujimoto
et al., 2008), we hypothesized that uremic solutes could also contribute
to the observed changes in the bile acid pool of CKD patients. Until
now, the kidney-liver axis has been studied either using animal models
or by investigating only a small subset of human hepatic transporters
(Naud et al., 2011; Naud et al., 2008; Sato et al., 2014). If and to what
extent individual uremic solutes interfere with human uptake and efflux
transporters of bile acids has not been studied systematically. The major
hepatic bile acid transporters involved in this process include Na+-
dependent taurocholate cotransporting polypeptide (NTCP) and or-
ganic anion transporting polypeptides (OATPs) at the basolateral
membrane of hepatocytes, as well as bile salt efflux pump (BSEP) and to
a minor extent multidrug resistance protein (MRP) 2 present at the
canalicular membrane. An alternative basolateral pathway for the ex-
port of conjugated bile acids during cholestasis is provided by MRP3,
and by MRP4 supposedly in cotransport with glutathione (Halilbasic
et al., 2013). Together, these transporters modulate bile acid uptake
from portal blood into hepatocytes, while also preventing cytotoxic bile
acid levels via their efflux from the hepatocyte. Although the role of the
transporters involved in bile acid transport is evident, a recent study
showed that interference with mitochondrial function can also con-
tribute to cholestatic liver injury (Aleo et al., 2014). In order to com-
prehensively chart relevant effects of uremic solutes on hepatic bile acid
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handling, we therefore also included studies to identify possible mi-
tochondrial effects of uremic solutes to investigate whether both me-
chanisms coincide in CKD-induced liver injury.
We studied the inhibitory potential of seven uremic solutes that are
inefficiently cleared in CKD patients (indoxyl sulfate, indole-3-acetic
acid, p-cresyl glucuronide, p-cresyl sulfate, hippuric acid, kynurenic
acid, and putrescine) on human bile acid uptake and efflux transporters.
In addition, we used qPCR analysis of individual transporter and cy-
tochrome P450 7A1 (CYP7A1, the rate-limiting enzyme involved in de
novo bile acid synthesis), mRNAs to study the potential of uremic so-
lutes to regulate expression of key hepatocellular components in bile
acid homeostasis. Finally, we investigated the functional consequences
of prolonged exposure of human hepatocytes to uremic solutes on bile
acid uptake and mitochondrial function.
2. Methods
2.1. Cell culture
HEK293 cells, which were used for uptake experiments, were cul-
tured in Dulbecco's Modified Eagle Medium with GlutaMAX™ (Thermo
Fisher Scientific), supplemented with 10% (v/v) Fetal Bovine Serum
(Greiner) at 37 °C and 5% (v/v) CO2. Primary human hepatocytes were
cultured at 37 °C and 5% (v/v) CO2 using Williams' B medium, which
was made in-house by combining Williams' E medium with 1% (m/v)
inulin transferring selenium, 1.0% (v/v) sodium pyruvate, 1.0% (v/v)
MEM-NEAA, 2.0% (v/v) penicillin-streptomycin, 1.0% (v/v) fungizone,
1.6 μM dexamethasone, and 10% (v/v) heat-inactivated human serum.
2.2. Isolation of primary human hepatocytes
Primary human hepatocytes were obtained from liver resection
waste material of patients undergoing surgical treatment. Informed
consent was obtained from every patient and the procedure was ap-
proved by the Medical Ethical committee Arnhem-Nijmegen, the
Netherlands. In short, the liver slice was perfused with HBSS-HEPES
buffer containing EDTA, followed by perfusion with HBSS-HEPES only.
Then, collagenase was added to the perfusion buffer, allowing the re-
lease of hepatocytes, followed by further dissection of the liver slice
into smaller lobes. The resulting cell suspension was filtered over a cell
strainer and centrifuged at 10g for 5min and subsequently washed with
DMEM, which was repeated several times. Cells were then resuspended
in Williams' B medium and centrifuged in 25% (v/v) percoll at 800g
followed by removal of dead cells. The resulting live cells were washed
once in Williams' E medium to remove any remaining percoll. Next,
cells were resuspended in Williams' B medium and, counted. Finally,
cells were seeded at 400,000 cells/well in a 12-well plate coated with
rat tail collagen.
2.3. Transduction of HEK293 cells for uptake inhibition experiments
HEK293 cells were seeded in 24-well plates coated with poly-D-ly-
sine (Corning) and incubated for 24 h at 37 °C and 5% (v/v) CO2. Then,
transduction was performed by adding 30 μL of baculovirus encoding
either the uptake transporter of interest or EYFP as a negative control.
OATP1B1 was expressed according to GenBank entry number
AF205071.1, OATP1B3 according to GenBank entry BC141525 and
OATP2B1 as NM_001145212. The sequence of NTCP was equal to
NM_003049.3 (Notenboom et al., 2018). Following addition of the
virus, sodium butyrate was added to a final concentration of 5mM.
After another 72-h incubation at 37 °C and 5% (v/v) CO2, uptake ex-
periments were performed.
2.4. Uptake experiments in HEK293 cells overexpressing transporters and
primary human hepatocytes
Using HEK293 cells expressing the transporter of interest (or EYFP
as a negative control) or primary human hepatocytes, radiolabeled
taurocholic acid (TCA) (Perkin-Elmer) inhibition by uremic solutes was
tested. In short, cells were washed once with 37 °C HBSS (Thermo
Fisher Scientific) followed by incubation with 37 °C HBSS containing
65 nM of radiolabeled TCA in the presence or absence of 500 μM of one
of the selected uremic solutes. Following incubation at 37 °C for 5min,
the cells were washed once with ice-cold HBSS containing 0.5% (m/v)
bovine serum albumin and twice with ice-cold HBSS. Then, the cells
were lysed by incubation with 1.0M NaOH at room temperature for
5min, followed by transfer of the cell lysate to counting vials, addition
of scintillation liquid and liquid scintillation analysis to determine the
amount of TCA uptake. Next, uptake rates were normalized to the
amount of cellular protein of the samples as determined by a Biorad
protein assay (Biorad). Inhibition studies in hepatocytes were designed
to study the consequences of regulation at the mRNA level by the in-
dividual uremic solutes on the function of the combined uptake trans-
porters. Therefore, primary human hepatocytes were pre-incubated
with only 500 μM of the individual uremic solutes for 72 h, followed by
extensive washing and a subsequent TCA uptake experiment. Hence, it
is important to note that during the uptake experiment no co-incuba-
tion with uremic solutes took place. Uptake experiments with radi-
olabeled TCA were performed in the same manner as described above
for the HEK293 cells.
2.5. Production of membrane vesicles
Vesicles were prepared by PharmTox (Radboudumc, Nijmegen, the
Netherlands), as described previously by our laboratory with minor
modifications (Ritschel et al., 2014; El-Sheikh et al., 2013). In brief,
transporters of interest, or enhanced Yellow Fluorescent Protein (EYFP)
as a control, were cloned behind a CMV promotor into a Baculovirus.
HEK293 cells were subsequently transduced with these viruses and
harvested by centrifugation. The sequence of MRP2 was equal to
NM_000392 except for three silent mutations at base pairs 264, 1167,
and 3972, of which C3972T is a known polymorphism. The sequence of
MRP3 was equal to NM_003786 (Wittgen et al., 2011). The sequence of
the MRP4 construct was equal to GenBank accession number NM_
005845 except for an I18L polymorphism, as described earlier by El-
Sheick et al. (El-Sheikh et al., 2007). BSEP was expressed as
NM_003742 (van Beusekom et al., 2013). The 100,000 g membrane
fraction of the cells transduced with individual transporters was
homogenized in ice-cold TS buffer (10mM Tris-HEPES and 250mM
sucrose, pH 7.4) and high shear passage through a 100 μm opening was
used to prepare membrane vesicles. Protein concentration of these ve-
sicles was determined using the Bio-Rad protein assay (Bio-Rad la-
boratories Inc., Veenendaal, the Netherlands). Vesicles were snap-
frozen in liquid nitrogen and stored until use at −80 °C.
2.6. Efflux transporter experiments
Using vesicles containing either the transporter of interest or EYFP,
(uremic solute-inhibited) uptake of radiolabeled TCA was tested.
Membrane vesicles were thawed and transferred to a 96-well plate, to a
mixture containing TS buffer, 10mM MgCl2, 4.0mM MgATP pH 7.0,
and 0.15 μM radiolabeled TCA in the presence or absence of 500 μM of
the selected uremic solute. Following incubation of the plate at 37 °C for
5min, the plate was put on ice and ice-cold TS buffer was added to stop
the reaction. The samples were then transferred to a 96-well filter plate
(Millipore) pre-incubated with TS buffer. The filter membrane was
washed twice again with ice-cold TS buffer. The membranes were then
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punched out of the filter plate and transferred to a counting vial, fol-
lowed by addition of 2.0mL of scintillation liquid before liquid scin-
tillation analysis. Next, efflux rates were normalized to the amount of
cellular protein present in the samples as determined by a Biorad pro-
tein assay (Biorad).
2.7. qPCR analysis
RNA was isolated from primary human hepatocytes exposed to
500 μM of uremic solutes or DMSO using the RNeasy® mini kit (Qiagen)
following incubation at 37 °C and 5% (v/v) CO2 for 72 h. Subsequently,
RNA was converted into cDNA using 300 ng of RNA, 0.625mM dNTPs
(Life Technologies), 0.25 μg/μL random primers (Thermo Fisher
Scientific), 10mM DTT (Promega), 20 U RNAsin (Promega), and 5% (v/
v) M-MLV (Thermo Fisher Scientific) in a total volume of 20 μL first-
strand buffer solution (Promega), which was incubated at 20 °C for
10min, 42 °C for 45min, and 95 °C for 10min. Then, 2.5 μL of the re-
sulting cDNA was mixed with 1.25 μL of primer-probe set (Applied
Biosystems) for the transporter of interest, 12.5 μL Taqman mastermix
(Applied Biosystems), and 8.75 μL of sterile MQ. The obtained results
were normalized against GAPDH values.
2.8. Cell viability analysis
Human primary hepatocytes were seeded in 384-wells black/clear
imaging plates (Greiner Bio-one), at a density of 4000 cells/well, 24 h
prior to treatment with uremic solutes. Four replicates of each uremic
solute were tested at 500 μM. After 72 h exposure, nuclei were stained
for cell viability analysis using Hoechst 33342 (10 μg/mL, Thermo
Fisher Scientific) in HEPES-Tris (HT) buffer (132mM NaCl, 10mM
HEPES, 4.2mM KCl, 1mM MgCl2, 1.0mM CaCl2 and 25mM D-glucose,
adjusted to pH 7.4 with Tris). After 25min of staining at 37 °C, cells
were washed twice with HT buffer and fluorescence was imaged on a
BD Pathway 855 high-throughput microscope (Becton Dickinson
Bioscience), followed by analysis of the number of nuclei using Image J
(Schneider et al., 2012).
2.9. Analysis of cellular reactive oxygen species
Human primary hepatocytes were seeded in 384-wells black/clear
imaging plates (Greiner Bio-one) and incubated with 500 μM of uremic
solute. After 72 h exposure, cells were loaded with 10 μM CM-H2DCFDA
(Thermo Fisher Scientific) in HT buffer for 25min at 37 °C. Next, the
cells were washed twice with HT buffer and imaged on a BD Pathway
855 high-throughput microscope (Becton Dickinson (BD) Bioscience).
CM-DCF images were processed using Image Pro Plus 6.3 software
(Media Cybernetics). A mask of the images was made to separate cel-
lular from background pixels; afterwards average CM-DCF intensity per
cellular pixel was determined.
2.10. Analysis of mitochondrial membrane potential
Human primary hepatocytes were seeded in 384-wells black/clear
imaging plates (Greiner Bio-one) and incubated with uremic solutes as
Fig. 1. TCA transport screen for uptake transporters.
HEK293 cells transiently overexpressing EYFP (control), NTCP (panel A), OATP1B1 (panel B), OATP1B3 (panel C), OATP2B1 (panel D) were incubated for 5min at
37 °C with HBSS containing 65 nM radiolabeled taurocholic acid (TCA). After removal of extracellular TCA, the amount of intracellular TCA was determined using
liquid scintillation analysis. Values represent mean ± SEM of three independent experiments, where * represents p < .05 using a paired t-test.
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described for cell viability analysis. To measure mitochondrial mem-
brane potential after 72 h of exposure to uremic solutes, cells were
loaded with 100 nM tetramethylrhodamine methyl ester (TMRM,
Thermo Fisher Scientific) for 25min at 37 °C, as described previously
(Distelmaier et al., 2008). Next, cells were maintained in HT buffer and
images were obtained on a BD Pathway 855 high-throughput micro-
scope. TMRM images were processed using Image Pro Plus 6.3 software
(Media Cybernetics). TMRM intensity analysis was performed on
background corrected images, which were masked to separate cellular
from background pixels.
2.11. Cellular ATP content
Total cellular ATP content was measured after exposure of human
primary hepatocytes to uremic solutes as described for the cell viability
analysis, using an ATP bioluminescence assay kit CLSII according to the
manufacturers protocol (Roche Applied Science). Briefly, cells were
harvested after which cellular ATP was released by addition of the cell
suspension to a boiling Tris-EDTA buffer (100mM Tris, 4.0mM EDTA,
pH 7.8) for 2min. Next, cells were diluted 1:1 with luciferase reagent,
followed by measurement of the bioluminescence signal. Finally, ATP
concentrations were calculated using a standard curve and divided by
the cell counts, measured as described above to obtain the total cellular
ATP content.
2.12. Cellular lactate production
After exposure of human primary hepatocytes to uremic solutes as
described for the cell viability analysis, the culture medium was col-
lected and lactate levels were quantified biochemically. Briefly, the
samples were diluted nine times in a 164mM hydrazine 64mM glycine
solution (pH 9.5) with 2mM NADH (Roche), after which the optical
density at 340 nm was determined. Next, the reaction was initiated by
the addition of L-lactate dehydrogenase (100 U/L, Roche). After 1 h of
incubation at room temperature, the optical density at 340 nm was
determined again. The lactate levels were determined by the increase in
the optical density at 340 nm and corrected for the number of cells to
obtain the cellular lactate production.
Fig. 2. TCA uptake inhibition by uremic solutes.
HEK293 cells transiently overexpressing NTCP (panel A), OATP1B1 (panel B), or OATP1B3 (panel C), were incubated for 5min at 37 °C with HBSS containing 65 nM
radiolabeled taurocholic acid (TCA) and 500 μM uremic solute or solvent control (Control). After removal of extracellular TCA, the amount of intracellular TCA was
determined using liquid scintillation analysis. Values were normalized to control: NTCP (0.09 ± 0.02 pmol/mg protein/min); OATP1B1 (0.03 ± 0.01 pmol/mg
protein/min); OATP1B3 (0.03 ± 0.01 pmol/mg protein/min). Values represent mean ± SEM of three independent experiments, where * represents p < .05 using
a repeated measures one-way ANOVA with Dunnett's post-hoc analysis.
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Fig. 3. TCA transport screen for efflux transporters.
Membrane vesicles containing either EYFP (control), BSEP (panel A), MRP2 (panel B), MRP3 (panel C), or MRP4 (panel D) were incubated for 5 min at 37 °C with
Tris-sucrose buffer containing MgATP, MgCl2, and 0.15 μM radiolabeled taurocholic acid (TCA). After removal of extracellular TCA, the amount of intravesicular TCA
was determined using liquid scintillation analysis. Values represent mean ± SEM of three independent experiments, where * and *** represent p < .05 and
p < .001, respectively, using a paired t-test.
Fig. 4. TCA efflux transporter inhibition by uremic solutes.
Membrane vesicles containing either BSEP (panel A) or MRP3 (panel B) were incubated for 5min at 37 °C with Tris-sucrose buffer containing MgATP, MgCl2, 0.15 μM
radiolabeled taurocholic acid (TCA) and 500 μM uremic solute or solvent control (Control). After removal of extracellular TCA, the amount of TCA inside the vesicles
was determined using liquid scintillation analysis. Values were normalized to control: BSEP (7.0⋅10−5 ± 1.7⋅10−5 pmol/mg protein/min); MRP3
(7.3⋅10−5 ± 1.7⋅10−5 pmol/mg protein/min). Values represent mean ± SEM of three independent experiments, where ** and *** represent p < .01 and
p < .001, respectively, using a repeated measures one-way ANOVA with Dunnett's post-hoc analysis.
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2.13. Data analysis
All data were collected from three independent experiments unless
stated otherwise. The data represented in Figs. 1 and 3 was tested using
a paired t-test, whereas the data presented in Figs. 2, 4–7 were tested
using repeated measures one-way ANOVA's with Dunnett's post-hoc
analysis to compare all samples against the vehicle-treated control. All
analyses were performed using Graphpad Prism 5.03 software and IBM
SPSS Statistics 22.
3. Results
3.1. Screening of uremic solute effects on TCA uptake
We selected taurocholic acid (TCA) as a prototypical substrate and
incubated HEK293 cells, transiently overexpressing human NTCP,
OATP1B1, OATP1B3, OATP2B1 or EYFP (negative control).
Transporter mediated uptake of radiolabeled TCA was determined by
the difference in uptake between the transporter-expressing and control
cells. The results of this screen are presented in Fig. 1, which illustrates
that three out of four uptake transporters mediated statistically sig-
nificant uptake of TCA: NTCP, OATP1B1 and OATP1B3. Of these three
transporters, NTCP showed at least tenfold higher levels of TCA uptake
compared to OATP1B3 and OATP1B1. For OATP2B1, no significant
uptake was observed, which is in line with its earlier reported low basal
TCA transport activity (Ogura et al., 2014). Based on these results, we
selected NTCP, OATP1B1 and OATP1B3 for further studies. The effect
of uremic solutes on the uptake of TCA was determined by incubating
HEK293 cells overexpressing one of the human bile acid uptake trans-
porters selected from the screen described above or EYFP (as a negative
control) with radiolabeled TCA, in the presence or absence of 500 μM of
one of the uremic solutes. Fig. 2 shows that a significant decrease to
46 ± 3% (p= .049) in TCA uptake by NTCP was observed in the
presence of p-cresyl sulfate, whereas the same compound increased the
amount of TCA uptake by OATP1B1.
Fig. 5. mRNA expression analysis of uptake transporters and CYP7A1.
Isolated primary human hepatocytes were exposed to 500 μM uremic solutes for 72 h before NTCP (panel A), OATP1B1 (panel B), OATP1B3 (panel C), or CYP7A1
(panel D) RNA was extracted, converted into cDNA and qPCR analysis using commercially available primer-probe sets for the genes of interest. Values represent
GAPDH corrected mean ± SEM of three independent experiments, where * and ** represent p < .05 and p < .01, respectively, using a repeated measures one-way
ANOVA with Dunnett's post-hoc analysis.
K.M. Weigand et al. Toxicology in Vitro 56 (2019) 52–61
57
3.2. Screening of uremic solute effects on TCA efflux
In order to study the effect of uremic solutes on TCA transport via
hepatic efflux transporters, a screen for radiolabeled TCA uptake using
vesicles containing BSEP, MRP2, MRP3, MRP4 or EYFP (as a negative
control) was performed. Based on the observed differences in TCA
uptake by the various vesicles as shown in Fig. 3, there was a statisti-
cally significant increase in the amount of TCA taken up by BSEP as well
as MRP3 compared to control vesicles. In our studies, MRP4 did not
transport TCA, also not in presence of 5mM reduced glutathione (data
not shown). Based on these results we selected BSEP and MRP3 for
further studies with TCA.
Next, we investigated the effect of the presence of uremic solutes on
TCA uptake by incubating vesicles containing BSEP, MRP3 or EYFP (as
a negative control) with radiolabeled TCA in the presence or absence of
500 μM of one of the selected uremic solutes. As shown in Fig. 4, BSEP
transport was solely inhibited in the presence of kynurenic acid,
whereas MRP3 was not inhibited by any of the selected uremic solutes.
In contrast, we found that both p-cresyl glucuronide and hippuric acid
significantly increased the amount of TCA transported by MRP3.
3.3. Regulation of bile acid uptake transporters and CYP7A1 by uremic
solutes
The effect of uremic solutes on expression of specific bile acid
transporters was studied by incubating primary human hepatocytes
with 500 μM of uremic solutes or vehicle for 72 h, followed by qPCR
analysis of mRNA of various uptake transporters as well as CYP7A1.
The results of this assay are presented in Fig. 5, where statistically
significant changes can be observed for various uremic solutes: both
indole-3-acetic acid and hippuric acid increased the amount of mRNA
coding for NTCP. Notably, incubation of primary human hepatocytes
with indoxyl sulfate significantly decreased the amount of mRNA of
NTCP, OATP1B3 and CYP7A1 to 41 ± 14% (p= .029), 27 ± 9%
(p= .029) and 10 ± 10% (p= .0095), respectively.
3.4. Effect of uremic solutes on uptake of TCA by primary human
hepatocytes
To study the consequences of regulation at the mRNA level by the
individual uremic solutes on the function of the combined uptake
transporters, primary human hepatocytes were incubated with 500 μM
of uremic solutes for 72 h followed by extensive washing and a sub-
sequent TCA uptake experiment. Hence, it is important to note that
during the uptake experiment no co-incubation with uremic solutes
took place. The results of this experiment are presented in Fig. 6, which
shows that the amount of TCA taken up by the cells following incuba-
tion with indoxyl sulfate decreased significantly to 54 ± 8%
(p= .0053). None of the other uremic solutes tested had an effect on
the amount of TCA taken up by the primary hepatocytes.
3.5. Effect of uremic solutes on mitochondrial function
Besides the role of cellular in- and efflux transporters, it has recently
been suggested that drug-induced liver injury is often a consequence of
a combination of transporter as well as mitochondrial-mediated
changes (Aleo et al., 2014). Therefore, we also explored the effects of
the uremic solutes on mitochondrial function. Although all uremic so-
lutes lowered cell viability remaining at the end of the 72 h incubation
period (Fig. 7, panel A), only five out of seven uremic solutes caused a
significant decrease of the cellular ATP content, as shown in panel B of
Fig. 7. Note that we expressed ATP content per cell, i.e. correcting for
the loss of cells. While putrescine did not lower the ATP levels, it did
significantly decrease the mitochondrial membrane potential, which
was accompanied by increased lactate levels, both suggestive for an
adverse effect on mitochondrial function, presented in panels C and D.
Except for kynurenic acid, all uremic solutes that lowered the cellular
ATP content induced a significant decrease of the mitochondrial
membrane potential as well, shown in panel C, further supporting an
adverse effect on mitochondria. Of all uremic solutes, only indole-3-
acetic acid did not affect any of the mitochondrial parameters, which
suggests that the observed toxicity is initiated via extra-mitochondrial
pathways. Surprisingly, none of the uremic solutes caused a significant
increase of the cellular reactive oxygen species (ROS) levels, as shown
in panel E.
4. Discussion
In this study, we investigated the effect of uremic solutes on hepatic
bile acid uptake, efflux and synthesis, as well as mitochondrial function
that could play a role in chronic kidney disease-induced liver injury.
To understand how chronic kidney disease affects the bile acid pool
composition, we first studied the effect of uremic solutes on TCA uptake
by hepatic transporters NTCP, OATP1B1 and OATP1B3. We found that
p-cresyl sulfate inhibited NTCP-mediated TCA uptake, whereas it sti-
mulated OATP1B1-mediated TCA uptake. Given the generally accepted
role of NTCP in uptake of conjugated bile acids (including TCA) and the
role of OATPs in uptake of unconjugated bile acids (Meier, 1995), this
finding could reflect a shift in bile acid pool composition via a direct
interaction. Here, NTCP inhibition could lead to accumulation of con-
jugated bile acids in blood, which represent the majority of the bile
acids present in blood. This change in bile acid pool composition could
even be furthered by the increase in OATP1B1 activity. If this effect also
takes place in vivo, this would lead to an increased extraction of mainly
unconjugated bile acids from the blood. The mechanism of this stimu-
latory effect is unknown, but can be explained by the existence of an
allosteric binding site that modulates the substrate transport site upon
binding, leading to the observed enhanced transport rates. The trans-
lational value of in vitro transporter inhibition has been well estab-
lished, whereas for stimulation this is not very well established al-
though the phenomenon is well known. Previously, we observed similar
in vitro results for the interaction of compounds with Organic Anion
Fig. 6. TCA uptake assay.
Isolated primary human hepatocytes were exposed to 500 μM uremic solutes for
72 h before cells were exposed to HBSS containing 65 nM radiolabeled tauro-
cholic acid (TCA). After removal of extracellular TCA, the cells were lysed and
the amount of TCA taken up was measured using liquid scintillation analysis.
Values were normalized to solvent control (Control, 2.1 ± 0.1 pmol/mg pro-
tein/min). Values represent mean ± SEM of four independent experiments,
where ** represents p < .01 using a repeated measures one-way ANOVA with
Dunnett's post-hoc analysis.
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Fig. 7. Mitochondrial dysfunction associates with uremic solutes-induced hepatotoxicity.
Cell viability was assessed after 96 h incubation of human primary human hepatocytes with 500 μM uremic solutes by determination of the number of nuclei, and was
normalized to solvent control (Control, 147 ± 25 nuclei), shown in panel A. The cellular lysate was used to determine the effects of uremic solutes on total cellular
ATP content, depicted in panel B. The effects on mitochondrial membrane potential were measured by the use of the cationic dye TMRM, and normalized to solvent
control (Control, 1571 ± 61 A.U.), as shown in panel C. Panel D displays cellular lactate levels, where lactate production was determined in the culture medium, and
normalized to solvent control (Control, 76 ± 17 pmol/cell). The effects on the cellular ROS generation (panel E) were determined using CM-H2DCFDA and
quantified by the fluorescence of the oxidized product (CM-DCF). Values were normalized to solvent control levels (Control, 1472 ± 120 A.U.). Values represent
mean ± SEM of three independent experiments, where *, ** and *** represent p < .05, p < .01 and p < .001, respectively, of a repeated measures one-way
ANOVA with Dunnett's post-hoc analysis.
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Transporter 1-mediated and MRP2-mediated methotrexate transport.
The in vivo consequences of those stimulatory effects also remain to be
elucidated (El-Sheikh et al., 2013).
We detected a decrease in BSEP-mediated TCA efflux by kynurenic
acid, whereas p-cresyl glucuronide and hippuric acid increased TCA
transport by MRP3. With regard to these two transporters, it is well
established that BSEP is involved in efflux of the majority of in-
tracellular bile acids, whereas MRP3 is believed to play a role under
conditions of increased intracellular bile acids, serving as an “emer-
gency” basolateral efflux pump when BSEP function alone is not suffi-
cient for bile acid clearance from the hepatocyte (Donner and Keppler,
2001; Soroka et al., 2001; Yang et al., 2013). Based on the differences in
efficacy of BSEP- and MRP3-mediated TCA transport, the inhibition of
BSEP is likely to have a stronger effect on bile acid pool composition.
This effect could directly contribute to development of CKD-induced
liver injury, as BSEP is expressed at the canalicular side of the hepa-
tocyte and is highly important in maintaining physiological bile acid
concentrations within the hepatocyte. In addition, inhibition of BSEP
could affect the (specific) bile acid concentration gradients, which
subsequently affect the transport rates of hepatic uptake transporters,
thus leading to changes in the bile acid pool composition in blood as
well.
We did not test FXR induction, but investigated the direct effect of
uremic solutes on the genes under regulation of FXR. Expression levels
of the hepatic bile acid uptake transporters NTCP, OATP1B1, and
OATP1B3 were studied, as well as the rate-limiting enzyme in de novo
bile acid formation, CYP7A1, after prolonged exposure of primary he-
patocytes to uremic solutes. Indole-3-acetic acid and hippuric acid in-
duced expression of NTCP, whereas an mRNA expression pattern re-
flective of liver injury was found after incubation of hepatocytes with
indoxyl sulfate. This pattern included decreases in expression of NTCP,
OATP1B3, and CYP7A1. The observation that indoxyl sulfate reduces
the expression of multiple uptake transporters as well as CYP7A1, all
under control of FXR, points towards a role for indoxyl sulfate in FXR
induction.
Although changes in mRNA levels are relevant with regard to acti-
vation of nuclear receptors, changes in protein expression and function
of uptake transporters translate more directly to the pathophysiological
situation. Therefore, we tested the effect of prolonged exposure of
primary hepatocytes to uremic solutes on bile acid uptake. Our findings
correlate highly with the results observed in the mRNA expression
analysis, as indoxyl sulfate exposure significantly decreased the amount
of TCA taken up by the cells, and none of the other compounds tested
showed changes in TCA uptake. Again, this points towards a role for
indoxyl sulfate in CKD-induced changes in bile acid handling by he-
patocytes.
In addition to transporter-mediated effects on bile acid levels, we
also tested the mitochondrial effects of uremic solutes to investigate
whether, in analogy to drug-induced liver injury, these two processes
could coincide. All uremic solutes decreased the cell viability present at
the end of the incubations, and five of them showed significant de-
creases in cellular ATP content as well. Of these five solutes, four re-
duced the mitochondrial membrane potential, whereas only two in-
creased cellular lactate production. The absence of effects on generation
of reactive oxygen species could be explained by the robust anti-oxidant
capacity of, amongst others, the high glutathione levels in hepatocytes
(Kaplowitz, 1981). Of all solutes tested, hippuric acid showed the most
prominent effects on mitochondria, indicating that this uremic solute
could mediate liver injury primarily via mitochondrial toxicity path-
ways. Importantly, indoxyl sulfate decreased cell viability and most
strongly reduced cellular ATP content and mitochondrial membrane
potential, indicating that it could induce hepatocyte dysfunction via
multiple pathways.
In conclusion, we studied the direct and indirect effects of various
uremic solutes on bile acid handling and observed direct inhibition of
bile acid uptake with p-cresyl sulfate, and inhibition of bile acid efflux
by kynurenic acid. We identified indoxyl sulfate as an indirect mod-
ulator of bile acid handling by changing the expression of (multiple)
uptake transporters. This study shows that uremic solutes accumulating
in blood of CKD patients could lead to altered hepatocyte function via
direct and indirect effects on bile acid transporters as well as bile acid
synthesis. In addition, we identified mitochondrial toxicity as a possible
contributing pathway, shedding further light on why CKD patients
show changes in bile acid pool size and composition.
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